Reviewing The Case For Capricor Therapeutics Inc. (CAPR) Going Higher


Renaissance Technologies LLC recently announced the acquisition of new stake in Capricor Therapeutics Inc. (NASDAQ:CAPR). The institutional investor has increased its shareholding in the Healthcare company by 91.86% to 0.2 million shares with purchase of 95185.0 shares. This fresh investment now brings its stake to 1.39% valued currently at $1.58 million. In addition, Northern Trust Investments, Inc.(.. raised its holdings by 0.15 million to 0.15 million shares.

With over 1.91 million Capricor Therapeutics Inc. (CAPR) shares trading Monday and a closing price of $6.03 on the day, the dollar volume was approximately $11.54 million. The shares have shown a positive weekly performance of 9.44% and its price on 08/31/20 gained nearly 14.64%. Currently, there are 19.72M common shares owned by the public and among those 19.22M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for CAPR have a consensus price objective of $12.00. The analysts have set the share’s price value over the next 12 months at a high of $12.00 and a low of $12.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Capricor Therapeutics Inc. stock is 2.00 for the next 12 months. But an upside of 49.75% will see the stock hit the forecast high price target while mean target price for the stock is $12.00.

Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 102,670 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 15,652 shares.

The top 3 mutual fund holders in Capricor Therapeutics Inc. are Vanguard Extended Market Index Fu, iShares Tr. – Micro Cap ETF, and Fidelity Extended Market Index Fu. Vanguard Extended Market Index Fu owns 76500.0 shares of the company’s stock, all valued at over $0.61 million. The company bought an additional 31481.0 shares recently to bring their total holdings to about 0.54% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.12% of the shares outstanding.

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) opened at $5.30, up $0.04 from a prior closing price of $5.26. However, the script later closed the day at $6.03, up 14.64%. The company’s stock has a 5-day price change of 9.44% and 25.36% over the past three months. CAPR shares are trading 371.09% year to date (YTD), with the 12-month market performance up to 153.36% higher. It has a 12-month low price of $0.88 and touched a high of $12.32 over the same period. Currently, 1.91 million shares have been traded, compared to an average intraday trading volume of 2.62 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.74%, 1.08%, and 80.22% respectively.

Institutional ownership of Capricor Therapeutics Inc. (NASDAQ: CAPR) shares accounts for 4.70% of the company’s 19.72M shares outstanding. Mutual fund holders own 3.56%, while other institutional holders and individual stakeholders account for 5.52% and 0.98% respectively.

It has a market capitalization of $115.11M and a beta (3y monthly) value of 6.92. The earnings-per-share (ttm) stands at -$1.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.10% over the week and 11.78% over the month.

Analysts forecast that Capricor Therapeutics Inc. (CAPR) will achieve an EPS of -$0.37 for the current quarter, -$0.36 for the next quarter and -$0.93 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.37 while analysts give the company a high EPS estimate of -$0.37. Comparatively, EPS for the current quarter was -$0.43 a year ago. Earnings per share for the fiscal year are expected to increase by 60.10%, and 36.30% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Capricor Therapeutics Inc. (CAPR) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the CAPR, a number of firms have released research notes about the stock. Maxim Group stated their Hold rating for the stock in a research note on December 26, 2018, with the firm’s price target at. H.C. Wainwright coverage for the Capricor Therapeutics Inc. (CAPR) stock in a research note released on January 26, 2018 offered a Buy rating with a price target of $8.60. H.C. Wainwright was of a view on September 15, 2017 that the stock is Buy, while Rodman & Renshaw gave the stock Buy rating on February 13, 2017, issuing a price target of $14. H.C. Wainwright on their part issued Buy rating on July 06, 2016.


Please enter your comment!
Please enter your name here